Eczema drug study for Kids' growth pulled before it started
NCT ID NCT07187089
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to see if dupilumab (Dupixent), an approved eczema drug, could improve growth and bone strength in children aged 6 to 12 with severe atopic dermatitis. It planned to enroll children whose eczema was not controlled by topical treatments. However, the study was withdrawn before any participants were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dupilumab (Dupixent)
- What this could lead to
- If this study had proceeded, it could have shown that dupilumab helps children with severe eczema grow taller and have stronger bones.
- What could go wrong
- The study was withdrawn before any participants enrolled, so no results are available. It is unknown if dupilumab affects growth or bone density in this age group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.